Exicure
AGREEMENT PRIVACY POLICY Address 400 Seaport Court, Suite 102 Redwood City, 94063 Tel 847.673.1700 Fax 847.556.6411 Copyright © Exicure, Inc. All Rights Reserved. Designed by …
Exicure, Inc. - Investor Relations
Nov 3, 2025 · Exicure, Inc. is an early-stage biotechnology company developing nucleic acid therapies targeting ribonucleic acid against validated targets to neurological disorders and hair loss.
Exicure, Inc. - News
May 28, 2025 · Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
Exicure, Inc. - Exicure, Inc. Enters into Purchase Agreements for $1.3 ...
Nov 14, 2024 · Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets.
Exicure Presents Positive Topline Phase 2 Data for Burixafor in ...
Dec 8, 2025 · About Exicure Exicure, Inc. (Nasdaq: XCUR) is a clinical-stage biotechnology company developing therapies to address key challenges in hematologic diseases.
Exicure, Inc. - Exicure, Inc. Partners with GPCR Therapeutics to Fuel ...
Dec 26, 2024 · Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets.
Exicure, Inc. - Exicure, Inc. Announces Shareholders Approve the $8.7 ...
Dec 20, 2024 · Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets.
Exicure, Inc. - Exicure, Inc. and Bluejay Therapeutics Inc. Enter into ...
Feb 5, 2024 · "Our partnership with Bluejay continues the development of cavrotolimod," said Paul Kang, Chief Executive Officer of Exicure. "Exicure has spent considerable resources to discover and …
Exicure, Inc. Reports Full Year 2024 Financial Results
Mar 18, 2025 · Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated …
Exicure, Inc. - Exicure, Inc. Announces Purchase Agreement with GPCR ...
Jan 22, 2025 · Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets.